Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Else Nutrition
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Valuation: Mid-case 12-month value of C$6.0/share === Edison values Else primarily on a DCF basis and flex for different scenarios. Edison's base case assumes a sales CAGR of 47% in years 4 to 10, followed by 15% in years 11β15 and 10% in years 16β20. Edison Investment Research assumes 2.0% terminal growth and a 15% terminal EBIT margin, resulting in a mid-case 12-month value of C$6.0. Edison also look at peer group analysis. Although there are not many directly comparable peers, Else trades on an FY22 EV/sales multiple of 6.6x versus a peer group of baby food and plant-based manufacturers on 3.0x. Given Elseβs disruptive model, Edison believes a premium is justified. On a more bullish scenario, assuming a faster roll-out and uptake of product, its fair value is C$10.4, and on more pessimistic assumptions its fair value is C$4.2, which still represents significant upside to current levels.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)